Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association

NEWTOWN, Pa., May 22, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced multiple presentations discussing clinical and non-clinical studies relating to their oral rigosertib plus azacitidine combination therapy for which a Phase 3 trial is being designed. In addition, SymBio, Onconova‚Äôs partner in Japan and Korea, will present Phase 1 data evaluating intravenous rigosertib in Japanese patients with recurrent/relapsed or refractory Myelodysplastic Syndromes.